G1 Therapeutics, Inc. (NASDAQ:GTHX) Director Sells $270,000.00 in Stock

G1 Therapeutics, Inc. (NASDAQ:GTHXGet Rating) Director Mark A. Velleca sold 20,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 20th. The stock was sold at an average price of $13.50, for a total transaction of $270,000.00. Following the sale, the director now directly owns 116,000 shares in the company, valued at approximately $1,566,000. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

G1 Therapeutics Stock Performance

Shares of GTHX stock traded down $0.16 during trading hours on Thursday, hitting $12.77. The company’s stock had a trading volume of 1,388,400 shares, compared to its average volume of 1,003,289. The company has a 50 day moving average of $12.18 and a 200 day moving average of $8.32. The stock has a market cap of $545.88 million, a PE ratio of -3.22 and a beta of 1.93. The company has a current ratio of 4.75, a quick ratio of 4.38 and a debt-to-equity ratio of 1.15. G1 Therapeutics, Inc. has a 12-month low of $3.84 and a 12-month high of $17.49.

G1 Therapeutics (NASDAQ:GTHXGet Rating) last released its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.92) EPS for the quarter, beating the consensus estimate of ($1.04) by $0.12. The business had revenue of $10.57 million for the quarter, compared to the consensus estimate of $9.00 million. G1 Therapeutics had a negative net margin of 608.36% and a negative return on equity of 140.17%. On average, sell-side analysts forecast that G1 Therapeutics, Inc. will post -3.51 EPS for the current fiscal year.

Institutional Trading of G1 Therapeutics

Large investors have recently made changes to their positions in the business. TD Asset Management Inc. boosted its holdings in shares of G1 Therapeutics by 100.0% in the 4th quarter. TD Asset Management Inc. now owns 20,418 shares of the company’s stock valued at $208,000 after acquiring an additional 10,209 shares during the last quarter. Ensign Peak Advisors Inc acquired a new position in shares of G1 Therapeutics in the 4th quarter valued at $79,000. Amalgamated Bank acquired a new position in shares of G1 Therapeutics in the 1st quarter valued at $44,000. Pinz Capital Management LP acquired a new position in shares of G1 Therapeutics in the 1st quarter valued at $1,418,000. Finally, Fisher Asset Management LLC lifted its stake in shares of G1 Therapeutics by 1.9% in the 1st quarter. Fisher Asset Management LLC now owns 2,311,138 shares of the company’s stock valued at $17,565,000 after purchasing an additional 43,064 shares during the period. 46.55% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Several research firms have weighed in on GTHX. HC Wainwright reissued a “buy” rating and set a $67.00 target price on shares of G1 Therapeutics in a research report on Friday, June 3rd. Wedbush boosted their target price on shares of G1 Therapeutics from $20.00 to $25.00 and gave the stock an “outperform” rating in a research report on Friday, September 16th. Finally, Needham & Company LLC dropped their target price on shares of G1 Therapeutics from $42.00 to $32.00 and set a “buy” rating on the stock in a research report on Thursday, August 4th. One analyst has rated the stock with a sell rating and five have assigned a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $36.83.

About G1 Therapeutics

(Get Rating)

G1 Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.

Featured Stories

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.